drugset / Trial / NCT04614337

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

NCT04614337

Phase 2 Completed 104 enrolled Lumos Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.

Timeline

Start
2020-12-31
Primary completion
2024-09-04
Completion
2024-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LUM-201 Unknown 0.8 mg/kg Oral
Subject LUM-201 Unknown 1.6 mg/kg Oral
Subject LUM-201 Unknown 3.2 mg/kg Oral
Comparator Somatropin Protein / enzyme biologic 34 ug/kg Subcutaneous

Indications